Compare VMD & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VMD | ALLO |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.5M | 252.9M |
| IPO Year | N/A | 2018 |
| Metric | VMD | ALLO |
|---|---|---|
| Price | $7.34 | $1.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 147.9K | ★ 2.5M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.92 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $254,794,000.00 | N/A |
| Revenue This Year | $20.05 | N/A |
| Revenue Next Year | $17.44 | $100.00 |
| P/E Ratio | $21.49 | ★ N/A |
| Revenue Growth | ★ 18.89 | N/A |
| 52 Week Low | $5.93 | $0.86 |
| 52 Week High | $8.62 | $3.78 |
| Indicator | VMD | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 59.78 | 49.50 |
| Support Level | $7.24 | $1.32 |
| Resistance Level | $7.36 | $1.52 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 63.10 | 28.57 |
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.